. 2019 Sep 20;21(1):153–164. doi: 10.1007/s10198-019-01117-3

Table 2.

Input parameters for the model

	Base case	Input DSA	Distribution	References
Costs
Gefitinib per cycle	€2526^a		Gamma	[27]
Erlotinib per cycle	€2260^a		Gamma	[27]
Afatinib per cycle	€2414^a		Gamma	[27]
Osimertinib per cycle	€6106^a		Gamma	[43]
Pemetrexed/cisplatin per cycle^b	€3029^a		Gamma	[27]
Best supportive care per cycle	€1775	1377; 2065^k	Gamma	[44]
Mutation test	€929	604; 906^k	Gamma	[45]
Tumour response assessment^c	€405	157; 236^k	Gamma	[45]
Outpatient visit	€83	65; 97^k	Gamma	[46]
Laboratory tests^d	€77	60; 89^k	Gamma	[26]
Drug administration	€271	210; 315^k	Gamma	[44]
CNS progression osimertinib	€535	428; 642	Gamma	[47]
CNS progression standard-TKI	€1250	1000; 1500	Gamma	[47]
End-of-life	€2196	1703; 2555^k	Gamma	[48]
Home care per hour	€11	9;13 ^k	Gamma	[49]
Indirect medical costs	€10,602^l	4578; 26,326	Gamma	[50]
Informal care per hour	€14	11; 17^k	Gamma	[49]
Travelling	€6^e	5; 7^k	Gamma	[46]
Productivity loss	€4068	3155; 4733^k	Gamma	[51]
ALT/AST increase	€464	360; 540^k	Gamma	[27]
Anaemia	€1953	1514; 2272^k	Gamma	[49]
Anorexia	€797	618; 927^k	Gamma	[52]
Asthenia	€813	631; 946^f,k	Gamma	[49]
Decreased appetite	€826	640; 961^k	Gamma	[49]
Decreased white blood cells	€1405	1089; 1634^g,k	Gamma	[49]
Diarrhoea	€2359	1830; 2744^k	Gamma	[49]
Dyspnoea	€467	362; 543^k	Gamma	[27]
Fatigue	€813	631; 946^k	Gamma	[49]
Febrile neutropenia	€3033	2353; 3,529^k	Gamma	[49]
Leukopenia	€1942	1507; 2260^k	Gamma	[49]
Nausea	€728	565; 847^k	Gamma	[49]
Neuropathy	€795	616; 924^k	Gamma	[49]
Neutropenia	€1405	1089; 1634^k	Gamma	[49]
Paronychia	€2359^j	1830; 2744^k	Gamma	[49]
Rash	€2359	1830; 2744^k	Gamma	[49]
Stomatitis	€4229	3280; 4920^k	Gamma	[53]
Vomiting	€728ⁱ	565; 847^k	Gamma	[49]
Utilities
Progression-free	0.71	0.67; 0.80	Beta	[40]
After progression	0.67	0.59; 0.75	Beta	[40]
After progression on second line	0.62	0.49; 0.74	Beta	[40]
Disutilities
ALT/AST increase	− 0	0; 0^k	Beta	[54]
Anaemia	− 0.125	− 0.10; − 0.15^k	Beta	[49]
Anorexia	− 0.142	− 0.114; − 0.170	Beta	[55]
Asthenia	− 0.074^f	− 0.037; − 0.110	Beta	[56]
Decreased appetite	− 0.048	− 0.016; − 0.080	Beta	[49]
Decreased white blood cells	− 0.090^g	− 0.060; − 0.120	Beta	[56]
Diarrhoea	− 0.047	− 0.016; − 0.078	Beta	[56]
Dyspnoea	− 0.256	− 0.204; − 0.307^k	Beta	[55]
Fatigue	− 0.074	− 0.037; − 0.110	Beta	[56]
Febrile neutropenia	− 0.090	− 0.058; − 0.122	Beta	[49]
Leukopenia	− 0.090	− 0.059; − 0.120	Beta	[49]
Nausea	− 0.048	− 0.016; − 0.080	Beta	[56]
Neuropathy	− 0.048	− 0.016; − 0.080	Beta	[49]
Neutropenia	− 0.090	− 0.060; − 0.120	Beta	[56]
Paronychia	− 0.033^j	− 0.009; − 0.056	Beta	[56]
Rash	− 0.033	− 0.009; − 0.056	Beta	[56]
Stomatitis	− 0.151	− 0.121; − 0.181^k	Beta	[57]
Vomiting	− 0.048	− 0.016; − 0.080	Beta	[56]
Body surface area	1.70	1.36; 2.04	Normal	[49]
Parameters survival distribution
Lambda OS chemotherapy	0.019		Normal
Gamma OS chemotherapy	1.203		Normal
Lambda OS gefitinib	0.020		Normal
Gamma OS gefitinib	1.203		Normal
Lambda OS erlotinib	0.019		Normal
Gamma OS erlotinib	1.203		Normal
Lambda OS afatinib	0.017		Normal
Gamma OS afatinib	1.203		Normal
Lambda OS osimertinib	0.012		Normal
Gamma OS osimertinib	1.203		Normal
Intercept OS second-line osimertinib	4.069		Normal
Intercept OS second-line pemetrexed/cisplatin	2.861		Normal
Lambda PFS chemotherapy	0.073		Normal
Gamma PFS chemotherapy	1.478		Normal
Lambda PFS gefitinib	0.031		Normal
Gamma PFS gefitinib	1.478		Normal
Lambda PFS erlotinib	0.026		Normal
Gamma PFS erlotinib	1.478		Normal
Lambda PFS afatinib	0.027		Normal
Gamma PFS afatinib	1.478		Normal
Lambda PFS osimertinib	0.013		Normal
Gamma PFS osimertinib	1.478		Normal
Intercept PFS second-line osimertinib	2.985		Normal
Intercept PFS second-line pemetrexed/cisplatin	1.885		Normal

CNS central nervous system, DSA deterministic sensitivity analysis, OS overall survival, PFS progression-free survival, ALT alanine aminotransferase; AST aspartate aminotransferase

^aCosts comprised of acquisition costs and pharmaceutical delivery costs; no drug wastage assumed

^bVolume pemetrexed/cisplatin based on a point estimate body surface of 1.70 m². Administration of 500 mg/m² pemetrexed and 75 mg/m² cisplatin each cycle

^cTumour response assessment comprised CT and MRI scans for tumour assessment

^dLaboratory costs comprised haematology, sputum, and biochemistry test, excluding mutation test

^eBased on 14 km (€0.19/km) plus parking costs (€3, –)

^fAssumed to be the same as fatigue

^gAssumed to be the same as neutropenia

^hAssumed to be the same rash

ⁱAssumed to be the same as nausea

^jAssumed to be the same as rash

^kParameters were varied with ± 20% of the mean

^l€10,602 are the average indirect medical costs over a lifetime horizon. Indirect medical costs ranged between €4578 and €26,326